Related Experiment Videos
[Pharmacokinetic and clinical evaluation of cefpirome in the pediatric field]
1Department of Pediatrics, School of Medicine, Showa University.
Insights
Cefpirome (CPR) demonstrated significant efficacy in pediatric infections, with a 95.7% clinical success rate. This cephalosporin showed favorable pharmacokinetics and a low incidence of side effects, suggesting its utility in treating infections in children.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Antimicrobial Agents
Background:
- Cefpirome (CPR) is a novel cephalosporin antibiotic.
- Pediatric infections require effective and safe antimicrobial treatments.
Purpose of the Study:
- To evaluate the pharmacokinetic and clinical efficacy of cefpirome in pediatric patients.
- To assess the safety profile of cefpirome in this population.
Main Methods:
- Pharmacokinetic analysis including peak serum concentrations and half-lives after varying intravenous drip infusions.
- Clinical efficacy assessment based on daily dose levels.
- Microbiological eradication rates and side effect monitoring.
Main Results:
- Peak serum concentrations ranged from 63.7 to 128.8 µg/ml with half-lives between 1.28 and 1.79 hours.
- Urinary excretion rates were high (66.7-77.1% in 6 hours).
- Clinical efficacy was 95.7%, with a 95.5% eradication rate for identified strains. Side effects were minimal (diarrhea in 2 cases).
Conclusions:
- Cefpirome exhibits favorable pharmacokinetic properties in children.
- CPR demonstrated high clinical efficacy and a good safety profile for pediatric infections.
- Cefpirome is a promising antimicrobial agent for use in pediatric infectious diseases.
Abstract:
Pharmacokinetic and clinical evaluations of cefpirome (CPR), a newly developed cephalosporin, were performed in the field of pediatrics. The results are summarized as follows. 1. Peak serum concentrations of CPR after a dose of 20 mg/kg via 30 minutes and that via 60 minutes intravenous drip infusion and a dose of 40 mg/kg via 60 minutes intravenous drip infusion were 80.8, 63.7 and 128.8 micrograms/ml, respectively, with half-lives being 1.41, 1.28 and 1.79 hours, respectively. Urinary excretion rates for CPR in the first 6 hours after administration ranged 66.7-77.1%. 2. The clinical efficacy rate in pediatric infections obtained at daily dose levels ranging 55.6-166.7 mg/kg was 95.7%. 3. The eradication rate for 22 strains identified in the study was 95.5%. 4. Side effects were found in 2 cases of diarrhea. The abnormal laboratory test results were observed in 5 cases with 7 test items (increased number of platelets; 2 cases, increased activity of GOT; 2 cases and increased activity of GPT; 1 case). According to these results, CPR was considered to be a useful antimicrobial agent in pediatric infections.